|
n
|
18
|
34
|
10
|
15
|
10
|
10
|
|
Age, mean ± SD, yr
|
37.9 ± 8.3
|
42.9 ± 14.0
|
30.9 ± 13.9
|
29.8 ± 10.5
|
37.1 ± 13.1
|
42.4 ± 12.7
|
|
Sex, male/female
|
10/5
|
13/21
|
5/5
|
11/4
|
8/2
|
8/2
|
|
Disease duration, median (range)
| |
12(6–240)
|
24(12–60)
|
24(10–120)
|
27(12–120)
|
27(9–120)
|
|
Montreal A (Age of onset, yr), n (%)
| | | | | | |
|
A1 (< 16)
| | |
0
|
1(6.7)
| | |
|
A2 (17 ~ 40)
| | |
8(80)
|
12(80)
| | |
|
A3 (> 40)
| | |
2 (20)
|
2(13.3)
| | |
|
Montreal A (Location), n (%)
| | | | | | |
|
L1 (ileal)
| | |
3(30)
|
5(33.3)
| | |
|
L2 (colonic)
| | |
4(40)
|
3(20)
| | |
|
L3 (ileocolonic)
| | |
3(30)
|
7(46.7)
| | |
|
L4 (upper gastrointestinal tract)
| | |
0
|
0
| | |
|
Montreal B (Behavior), n (%)
| | | | | | |
|
B1 (nonstricturing, nonpenetrating)
| | |
9(90)
|
13(86.7)
| | |
|
B2 (stricturing)
| | |
1(10)
|
1(6.7)
| | |
|
B3 (penetrating)
| | |
0
|
1(6.7)
| | |
|
Montreal E, n (%)
| | | | | | |
|
E1 (ulceration proctitis)
| | | | |
3(30)
|
3(30)
|
|
E2 (left-sided ulceration colitis)
| | | | |
3(30)
|
4(40)
|
|
E2 (extensive ulceration colitis)
| | | | |
4(40)
|
3(30)
|
|
Therapy, n (%)
| | | | | | |
|
5-ASA
| | |
2(20)
|
1(6.7)
|
8(80)
|
7(70)
|
|
Azathioprine
| | |
3(30)
|
2(13.3)
|
0(0)
|
0(0)
|
|
Steroids
| | |
0(0)
|
0(0)
|
2(20)
|
3(30)
|
|
Infliximab
| | |
5(50)
|
11(73.3)
|
0(0)
|
0(0)
|
|
Nutritional treatment
| | |
1(10)
|
2(13.3)
|
0(0)
|
0(0)
|
